General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-20 | 2024-03 | 0 | N/A | N/A | N/A |
2023-02-28 | 2022-12 | -0.19 | N/A | N/A | N/A |
2022-11-08 | 2022-09 | -0.25 | -0.2 | 0.05 | 20.00% |
2022-08-15 | 2022-06 | -0.23 | -0.31 | -0.08 | -34.78% |
2022-05-05 | 2022-03 | 0 | N/A | N/A | N/A |
2022-04-01 | 2021-12 | -0.3 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-11-02 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-03-25 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-09 | HC Wainwright & Co. | Upgrade | Buy | |
2021-01-21 | Alliance Global Partners | Upgrade | Buy | |
2020-07-31 | HC Wainwright & Co. | Upgrade | Buy | |
2020-05-26 | Dawson James | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-09-12 | ABG MANAGEMENT, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2021-03-15 | ASGHAR NAJJAM | Chief Financial Officer | 56.97K | Stock Award(Grant) |
2018-01-23 | ASIA PACIFIC MEDTECH BVI, LTD. | Beneficial Owner of more than 10% of a Class of Security | 8.62M | Sale |
2020-12-15 | FOLLOWWILL DORMAN | Director | 2.13K | Sale |
2021-12-26 | JANDA KIM D | Director | 3.00K | Sale |
2022-12-20 | JI HENRY H | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | State Street Corporation | 50.64M | 15.56M | 10.73% |
2022-12-30 | Blackrock Inc. | 39.42M | 12.11M | 8.35% |
2022-12-30 | Vanguard Group, Inc. (The) | 29.54M | 9.08M | 6.26% |
2022-12-30 | Geode Capital Management, LLC | 8.91M | 2.74M | 1.89% |
2022-12-30 | B. Riley Financial, Inc. | 5.22M | 1.60M | 1.11% |
2022-12-30 | B. Riley Securities, Inc. | 5.22M | 1.60M | 1.11% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 40.89M | 12.56M | 8.66% |
2022-09-29 | Vanguard Total Stock Market Index Fund | 12.84M | 3.95M | 2.72% |
2022-12-30 | iShares Russell 2000 ETF | 10.36M | 3.18M | 2.20% |
2022-09-29 | Vanguard Extended Market Index Fund | 5.51M | 1.69M | 1.17% |
2022-12-30 | Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh | 4.27M | 1.31M | 0.91% |
2022-12-30 | iShares Russell 2000 Value ETF | 4.11M | 1.26M | 0.87% |
Split | Date |
---|---|
0.04 : 1 | 2013-08-01 |
0.1 : 1 | 2008-10-07 |
Reversal
Revenue
Sales
Exposure
Want to come in California , Europe ,Brazil ,Canada ,Mexico ,and someday when the FDA guess they’re head out of the ass!!! The USA!
Test is the answer
Therapeutic’s is also the answer
That’s revenue!!!!! And there will be more !!!
Imagine all these others countries have access to more accurate test than the USA.
Brazil
Mexico
Europe
$
The state of California
The USA military
It’s time for the fda to approve Covid stix!
$OCGN -buy today WHO approval this tues get in cheap while you can.
50% more volume and Ji’s shares sell it down, get a replacement already.
Dear Robinhood, $SRNE needs to be noticed!
All of the EU union !
Plus Mexico
Plus California
That a lot of people !
Go Sorrento!
This country’s are in the CE approval